Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

European Journal of Cancer - Tập 107 - Trang 142-152 - 2019
Dan P. Zandberg1, Alain P. Algazi2, Antonio Jimeno3, James Good4, Jérôme Fayette5, Nathaniel Bouganim6, Neal Ready7, Paul Clement8, Caroline Even9, Raymond Jang10, Stuart J. Wong11, Ulrich Keilholz12, Jill Gilbert13, Moon J. Fenton14, Irene Braña15, Stéphanie Henry16, Éva Remenár17, Zsuzsanna Pápai18, Lillian L. Siu10, Anthony Jarkowski19, J. Armstrong19, Kobby Asubonteng19, Jean Fan19, Giovanni Melillo19, Ricard Mesı́a20
1University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA
2University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
3Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, USA
4Institute of Head and Neck Studies and Education, Queen Elizabeth Hospital, Birmingham, UK
5Clinical Oncology, Cancer Center Centre Léon Bérard, University of Lyon, Lyon, France
6Department of Oncology, McGill University Health Centre, Montréal, QC, Canada
7Duke University Medical Center, Durham, NC USA
8Department of Oncology, Leuven Cancer Institute, KU Leuven, Belgium
9Department of Head and Neck Oncology, Institut Gustave Roussy, Villejuif, France
10Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
11Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
12Charité Comprehensive Cancer Center, Berlin, Germany
13Henry-Joyce Cancer Clinic, Nashville, TN, USA
14The West Cancer Center, University of Tennessee Health Science Center, Memphis, TN, USA
15Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
16Department of Oncology-Hematology, Radiotherapy, and Nuclear Medicine, CHU UCL Namur, Namur, Belgium
17National Institute of Oncology (Országos Onkológiai Intézet), Budapest, Hungary
18State Health, Center Higatian Defanse Forses, Budapest, Hungary
19AstraZeneca, Gaithersburg, MD, USA
20Medical Oncology Department, Catalan Institute of Oncology, University of Barcelona, IDIBELL, Barcelona, Spain

Tóm tắt

Từ khóa


Tài liệu tham khảo

Leon, 2005, A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy, Clin Oncol (R Coll Radiol), 17, 418, 10.1016/j.clon.2005.02.014

Vermorken, 2007, J Clin Oncol, 25, 2171, 10.1200/JCO.2006.06.7447

Zenda, 2007, Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN), Jpn J Clin Oncol, 37, 477, 10.1093/jjco/hym059

Stewart, 2009, Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected], J Clin Oncol, 27, 1864, 10.1200/JCO.2008.17.0530

Kushwaha, 2015, Gefitinib, methotrexate and methotrexate plus 5-fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma, Cancer Biol Ther, 16, 346, 10.4161/15384047.2014.961881

Chau, 2016, Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts), J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.6052

Allen, 2015, Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches, Cancers (Basel), 7, 2397, 10.3390/cancers7040900

Chow, 2016, Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort, J Clin Oncol, 34, 3838, 10.1200/JCO.2016.68.1478

Bauml, 2017, Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study, J Clin Oncol, 35, 1542, 10.1200/JCO.2016.70.1524

Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252

Seiwert, 2016, Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol, 17, 956, 10.1016/S1470-2045(16)30066-3

Cohen, 2017, Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial, Ann Oncol, 28, 10.1093/annonc/mdx440.040

2018

2018

Segal, 2014, A phase 1 multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody MEDI4736: preliminary data, Ann Oncol, 25, 10.1093/annonc/mdu342.11

Segal, 2016, Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort (abstr 949O), Ann Oncol, 27, 328, 10.1093/annonc/mdw376.01

Rebelatto, 2016, Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma, Diagn Pathol, 11, 95, 10.1186/s13000-016-0545-8

Wildsmith, 2018, PD-L1 expression in patients screened for phase 2 head and neck squamous cell carcinoma clinical studies (HAWK and CONDOR)

Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J Clin Oncol, 34, 3119, 10.1200/JCO.2016.67.9761

ClinicalTrials.gov. Study of MEDI4736 monotherapy and in combination with tremelimumab versus standard of care therapy in patients with head and neck cancer (EAGLE). https://www.clinicaltrials.gov/ct2/show/NCT02369874?term=NCT02369874&rank=1. [Accessed October 25 2018].

ClinicalTrials.gov. Phase III open label study of MEDI 4736 with/without tremelimumab versus standard of care (SOC) in recurrent/metastatic head and neck cancer (KESTREL). https://www.clinicaltrials.gov/ct2/show/NCT02551159?term=NCT02551159&rank=1. [Accessed October 25 2018].

Siu, 2018, A randomized, open-label, multicenter, global phase 2 study of durvalumab (D), tremelimumab (T), or D plus T, in patients with PD-L1 low/negative recurrent or metastatic head and neck squamous cell carcinoma: CONDOR [abstract]

Thông tin
Thông tin xuất bản

European Journal of Cancer

Tập 107

142-152

Thông tin tác giả